Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211) Meeting Abstract
| Authors: | Usmani, S. Z.; Hoering, A.; Ailawadhi, S.; Sexton, R.; Lipe, B.; Valent, J. N.; Rosenzweig, M. A.; Zonder, J. A.; Dhodapkar, M. V.; Callander, N. S.; Zimmerman, T. M.; Voorhees, P. M.; Durie, B. G.; Rajkumar, S. V.; Richardson, P. G.; Orlowski, R. Z. |
| Abstract Title: | Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302091 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.8054 |
| Notes: | Meeting Abstract: 8054 -- Meeting also held virtually -- Source: Wos |
